glp 1 glp 2 glp 3 The Possible Involvement of Glucagon-like Peptide-2 in the Regulation of Food Intake through the Gut–Brain Axis GLP-3 RT (LY3437943) — Triple-Action

More comprehensive research is needed to establish standardized guidelines for integrating nutrition with GLP-1 therapies

Potential risks include: Immune reactions Injection site reactions Hormonal disruption (with GH-related peptides) Contamination risk if sourced improperly Dosing variability Limited long-term safety data Most peptides lack large-scale, long-duration randomized controlled trials

Framing it that way is more useful than either dismissing fatigue or treating it as inevitable

For many individuals, these medications provide meaningful medical benefits, including improved blood sugar control, reduced cardiovascular risk, and significant weight reduction